Abstract
Iododoxorubicin 80 mg m-2 i.v. was given 3 weekly for a maximum of six cycles as first-line chemotherapy to 14 evaluable women with metastatic breast cancer. The response rate was 14% (95% confidence intervals 4-40%); median time to progression was 3.5 months (range 0.7 to > 9.3) and median survival was 10.2 months (range 2.3 to > 20.4). Neutropenia was the main toxicity but was not associated with severe sepsis. Two patients had a significant (> 10%) but asymptomatic fall in cardiac ejection fraction; other toxicities were mild. Plasma pharmacokinetics was studied during the first cycle of treatment. Iododoxorubicin was extensively metabolised to iododoxorubicinol. Neutropenia and thrombocytopenia were both significantly correlated with the area under the concentration-time curve (AUC) for iododoxorubicin and the total AUC for iododoxorubicin and iododoxorubicinol. Quality of life (QOL), evaluated by self-report questionnaire and interview, showed little evidence of benefit in terms of physical symptom relief, level of activity, psychological symptoms or global evaluation of QOL during treatment. Iododoxorubicin is subjectively less toxic than standard anthracyclines, but at the dose and schedule used has limited activity in metastatic breast cancer, possibly because iododoxorubicinol is not clinically active.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Twelves, C., Dobbs, N., Lawrence, M. et al. Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. Br J Cancer 69, 726–731 (1994). https://doi.org/10.1038/bjc.1994.137
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.137
This article is cited by
-
Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer
Health and Quality of Life Outcomes (2016)
-
Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007
Journal of Experimental & Clinical Cancer Research (2008)
-
Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise
British Journal of Cancer (1999)
-
Evaluation of quality of life for diverse patient populations
Breast Cancer Research and Treatment (1996)
-
Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry
Cancer Chemotherapy and Pharmacology (1995)